[DOI] [PMC free article] [PubMed] [Google Scholar] 97.Guo J, Bakshi V, Lin AL
Although preliminary regulatory-led analyses of post-marketing data have not found conclusive evidence of a causal link [14], and in the absence of evidence from large, randomised clinical trials, observational studies adequately designed to assess the comparative safety of treatments, employing an active comparator, new user design, are warranted to evaluate the risk of SIS in individuals treated with GLP-1RA
Among the 10 PDPs offered in most or all PDP regions, most charge $0 for preferred generics but only 1 PDP charges flat copayments for preferred brands and all charge coinsurance for non-preferred drugs Part D enrollees in 8 of the 10 national or near-national PDPs face a median copayment of $0 for preferred generics, while median copays for drugs on the standard generic tier range from $0 to $10 (Figure 9)
The route changes the technique, not the vitamin
doi:10.1186/s12885-024-12044-9